JP7458368B2 - 筋疾患のミトコンドリア増強療法 - Google Patents
筋疾患のミトコンドリア増強療法 Download PDFInfo
- Publication number
- JP7458368B2 JP7458368B2 JP2021502836A JP2021502836A JP7458368B2 JP 7458368 B2 JP7458368 B2 JP 7458368B2 JP 2021502836 A JP2021502836 A JP 2021502836A JP 2021502836 A JP2021502836 A JP 2021502836A JP 7458368 B2 JP7458368 B2 JP 7458368B2
- Authority
- JP
- Japan
- Prior art keywords
- mitochondria
- stem cells
- human
- cells
- mitochondrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002438 mitochondrial effect Effects 0.000 title claims description 124
- 208000029578 Muscle disease Diseases 0.000 title claims description 86
- 238000002560 therapeutic procedure Methods 0.000 title description 31
- 210000003470 mitochondria Anatomy 0.000 claims description 384
- 210000000130 stem cell Anatomy 0.000 claims description 337
- 210000004027 cell Anatomy 0.000 claims description 204
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 113
- 239000008194 pharmaceutical composition Substances 0.000 claims description 94
- 230000035772 mutation Effects 0.000 claims description 69
- 238000011282 treatment Methods 0.000 claims description 68
- 230000001717 pathogenic effect Effects 0.000 claims description 59
- 208000021642 Muscular disease Diseases 0.000 claims description 55
- 210000001185 bone marrow Anatomy 0.000 claims description 54
- 208000012268 mitochondrial disease Diseases 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 108091093105 Nuclear DNA Proteins 0.000 claims description 28
- 230000037396 body weight Effects 0.000 claims description 28
- 108010058682 Mitochondrial Proteins Proteins 0.000 claims description 25
- 102000006404 Mitochondrial Proteins Human genes 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 18
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 15
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 11
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 11
- 208000016334 muscle symptom Diseases 0.000 claims description 11
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 10
- 208000007101 Muscle Cramp Diseases 0.000 claims description 7
- 208000005392 Spasm Diseases 0.000 claims description 7
- 230000002411 adverse Effects 0.000 claims description 7
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 claims description 6
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 claims description 6
- 108010069201 VLDL Cholesterol Proteins 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 6
- 230000002407 ATP formation Effects 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 210000003630 histaminocyte Anatomy 0.000 claims description 5
- 230000009851 immunogenic response Effects 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 210000002200 mouth mucosa Anatomy 0.000 claims description 5
- 208000010428 Muscle Weakness Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000003651 basophil Anatomy 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000003593 megakaryocyte Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 210000001167 myeloblast Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 4
- 210000004180 plasmocyte Anatomy 0.000 claims description 4
- 210000001626 skin fibroblast Anatomy 0.000 claims description 4
- 238000007910 systemic administration Methods 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 3
- 206010028648 Myopathy toxic Diseases 0.000 claims description 3
- 208000023137 Myotoxicity Diseases 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 208000034819 Mobility Limitation Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 230000009194 climbing Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 claims 21
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 claims 1
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 claims 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 104
- 239000000203 mixture Substances 0.000 description 75
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 55
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 55
- 102000006732 Citrate synthase Human genes 0.000 description 55
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 44
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 43
- 230000006870 function Effects 0.000 description 40
- 208000013234 Pearson syndrome Diseases 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 230000008014 freezing Effects 0.000 description 33
- 238000007710 freezing Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 29
- 238000011534 incubation Methods 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 238000010257 thawing Methods 0.000 description 24
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 23
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- 239000000872 buffer Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 210000002798 bone marrow cell Anatomy 0.000 description 18
- 230000008859 change Effects 0.000 description 17
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 12
- 102000008100 Human Serum Albumin Human genes 0.000 description 12
- 108091006905 Human Serum Albumin Proteins 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 11
- 108010088751 Albumins Proteins 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 201000009623 Myopathy Diseases 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 210000001700 mitochondrial membrane Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000018832 Cytochromes Human genes 0.000 description 7
- 108010052832 Cytochromes Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 230000021824 exploration behavior Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000008774 maternal effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 5
- 201000006328 Fanconi syndrome Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- -1 coatings Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000004898 mitochondrial function Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002617 apheresis Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 210000001768 subcellular fraction Anatomy 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001085 differential centrifugation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000008437 mitochondrial biogenesis Effects 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000003014 totipotent stem cell Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 102100029344 ATP synthase protein 8 Human genes 0.000 description 2
- 208000027205 Congenital disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000700892 Homo sapiens ATP synthase protein 8 Proteins 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 210000003492 pulmonary vein Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010825 rotarod performance test Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 102100021921 ATP synthase subunit a Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101150118155 Cd34 gene Proteins 0.000 description 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 102100028203 Cytochrome c oxidase subunit 3 Human genes 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101710121304 Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000753741 Homo sapiens ATP synthase subunit a Proteins 0.000 description 1
- 101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001109060 Homo sapiens NADH-ubiquinone oxidoreductase chain 4L Proteins 0.000 description 1
- 206010071353 Hypermagnesuria Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 102100021452 NADH-ubiquinone oxidoreductase chain 4L Human genes 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 1
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000004205 endocrine pancreatic function Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 210000002375 erythropoietic cell Anatomy 0.000 description 1
- 230000004204 exocrine pancreatic function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 238000010852 mitochondrial transfer Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- NBAOBNBFGNQAEJ-UHFFFAOYSA-M tetramethylrhodamine ethyl ester perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 NBAOBNBFGNQAEJ-UHFFFAOYSA-M 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
Description
ミトコンドリアの含有量および活性を増加させるために、異なるマウス細胞を、単離されたマウスまたはヒトのミトコンドリアとともに、DMEM(24時間、37℃、5%CO2)中でインキュベートした。表1は、プロセス前の細胞のCS活性と比較した、プロセス後の細胞のCS活性の相対的な増加によって決定される、ミトコンドリア増強療法プロセスの代表的な結果を示す。
ミトコンドリアはC57/BLマウス(野生型mtDNAのドナー)の胎盤から単離された。骨髄細胞はFVB/Nマウス(ATP8にmtDNA突然変異を担持する)から単離された。FVB/N細胞は、C57/BL外因性ミトコンドリア(1×106個の細胞あたり4.4Uのミトコンドリア)をロードされ、その後、FVB/NマウスにI.V.注射で戻された。その後、FVB/Nマウスは種々の時点で屠殺され、器官の生体内分布が試験された。
患者1は、ピアソン症候群と診断された6.5歳の男児患者であり、mtDNAのヌクレオチド5835~9753が欠失している。ミトコンドリア増強療法(MAT)の前の彼の体重は14.5KGであった。彼の成長は治療前の3年間大幅に遅れ、1年以上胃瘻管(G-チューブ)によって栄養補給されていたにもかかわらず、改善しなかった。患者は腎不全(GFR 22ml/分)、電解質補給を必要とする近位尿細管症、およびカルシウム補給を必要とする副甲状腺機能低下症を有した。
患者2は、ピアソン症候群と診断された7歳の女児患者であり、mtDNAの4977ヌクレオチドが欠失している。患者はまた、貧血、内分泌膵機能不全を患っており、かつ糖尿病である(ヘモグロビンA1C 7.1%)。患者は、乳酸値が高く(>25mg/dL)、体重が少なく、食事および体重増加に問題がある。患者はさらに高マグネシウム尿症(高レベルの尿中マグネシウム、低レベルの血中マグネシウム)を患っている。患者は、記憶および学習の問題、乱視があり、TMRE、ATP含有量、およびO2消費率(健康な母親と比較して)によって決定される末梢リンパ球のミトコンドリア活性が低い。
患者3は、ピアソン症候群と診断された10.5歳の女児患者であり、mtDNAのヌクレオチド12113~14421が欠失している。患者は、貧血、および腎不全ステージ4に発展したファンコニー症候群も患っていた。患者は週に3回透析で治療された。過去2ヶ月で、患者は、重度の視力障害、視野の狭小化、および近見視力の喪失も患っていた。患者は身体活動をまったく行うことができなかった(歩くことはなく、ベビーカーに座っている)。患者の乳酸レベルは高く(>50mg/dL)、インスリンで治療された膵臓障害を有した。脳MRIは多くの病変および萎縮領域を示した。患者は、胃瘻造設術によってのみ栄養補給された。患者には記憶および学習の問題があった。患者は、テトラメチルローダミンエチルエステル(TMRE)、ATP含有量、およびO2消費率(健康な母親と比較して)試験によって決定される末梢リンパ球のミトコンドリア活性が低かった。
患者4は、14歳、19.5kgの女児患者で、カーンズ・セイヤー症候群と診断され、トンネル状視野、眼瞼下垂、眼筋麻痺、および網膜萎縮を経験していた。患者は、視力の問題、CPEO、てんかん発作、病的EEG、座位または歩行障害を伴う重度のミオパチー、心不整脈を有した。患者は、ミトコンドリアDNAに7.4Kbの欠失があり、これには次の遺伝子が含まれる:TK、NC8、ATP8、ATP6、CO3、TG、ND3、TR、ND4L、TH、TS2、TL2、ND5、ND6、TE、NC9、およびCYB。
中年(12ヶ月齢)C57BL/6Jマウスは、ミトコンドリア富化骨髄(BM)細胞(MNV-BM-PLC、1×106個の細胞、n=24)、骨髄細胞(BM、1×106細胞、n=23)、または対照ビヒクル溶液(VEHICLE、0.9%w/vのNaCl中4.5%のアルブミン、n=23)のいずれかを投与され、投与は約3ヶ月ごとに繰り返された。初回投与の1週間前および初回投与の9ヶ月後に、マウスは開放地での行動試験に供された。
図7A~7Bに示される結果は、MNV-BM-PLCで処理されたマウスが、広範な探索行動、アリーナの中央で過ごす時間の増加を呈したことを示し、この増加は、BM対照群の中央期間と比較して統計的に有意であった。
全体的運動能力および協調は、ミトコンドリア強化骨髄(BM)細胞(MNV-BM-PLC、1×106個の細胞、n=24)、骨髄細胞(BM、1×106細胞、n=23)、または対照ビヒクル溶液(VEHICLE、0.9%w/vのNaCl中4.5%のアルブミン、n=23)のいずれかを投与された中年(12ヶ月齢)C57BL/6Jマウスにおいて、Rotarod装置を使用して評価された。
骨格筋機能が、ミトコンドリア富化(増強)BM細胞(MNV-BM-PLC、106個の細胞、n=24)、骨髄細胞(BM、106細胞、n=23)、またはビヒクル溶液(VEHICLE、0.9%w/vのNaCl中4.5%のアルブミン、n=23)のいずれかを投与された中年(12ヶ月齢)C57BL/6Jマウスの前肢の握力によって評価された。
標題:筋疾患および障害を有する患者におけるミトコンドリアで富化された幹細胞の移植の安全性、生着、および治療効果を評価するための第I/II相非盲検単回投与臨床試験。
Claims (15)
- 筋疾患、障害、またはそれらの症状の治療を必要とするヒト患者において、かかる治療に使用するための医薬組成物であって、前記医薬組成物が、細胞の生存能力を支援することができる薬学的に許容可能な液体培地中、前記患者の体重1キログラムあたり少なくとも105~2×107個のヒトCD34 + 幹細胞を含み、
前記ヒトCD34 + 幹細胞は、ヒト外因性ミトコンドリアで富化され、
前記筋疾患または障害は、ミトコンドリアDNAの病原性突然変異によってまたはミトコンドリアタンパク質をコードする核DNAの病原性突然変異によって引き起こされるミトコンドリア病または障害ではなく、
前記医薬組成物は、全身投与のために製剤化される、
医薬組成物。 - 前記富化が、百万個の細胞あたり少なくとも0.044~最大176ミリユニットのCS活性のミトコンドリアの用量を前記ヒトCD34 + 幹細胞に導入することを含むか、または
前記富化が、百万個の細胞あたり0.88~最大17.6ミリユニットのCS活性のミトコンドリアの用量と前記ヒトCD34 + 幹細胞を接触させることを含む、
請求項1に記載の医薬組成物。 - 前記ヒト外因性ミトコンドリアが、同系または同種異系である、請求項1または請求項2に記載の医薬組成物。
- 前記疾患もしくは障害が、後天性ミトコンドリア機能障害に関連しているか、または
前記疾患もしくは障害が、後天性ミトコンドリア機能障害に関連していないか、または
前記疾患もしくは障害が、筋ジストロフィー、筋消耗疾患、心筋症、心筋虚血、炎症性ミオパシー、および中毒性ミオパシーからなる群から選択されるか、または
前記症状が、筋力低下、歩行困難、階段を登ることの困難、筋痙攣、硬直、攣縮、高トリグリセリドレベル、高総コレステロールレベル、および高VLDLコレステロールレベルからなる群から選択される、
請求項1~3のいずれか一項に記載の医薬組成物。 - 前記患者の体重1キログラムあたり約106個のミトコンドリア富化ヒトCD34 + 幹細胞を含むか、または
ヒトミトコンドリアで富化された合計約5×105~5×109個のヒトCD34 + 幹細胞を含む、
請求項1~4のいずれか一項に記載の医薬組成物。 - 前記ミトコンドリア富化ヒトCD34 + 幹細胞が、ミトコンドリア富化前の前記ヒトCD34 + 幹細胞における対応するレベルと比較して、
(i)増加したミトコンドリアDNA含有量、
(ii)増加したCS活性レベル、
(iii)SDHAおよびCOX1から選択される少なくとも1つのミトコンドリアタンパク質の増加した含有量、
(iv)増加したO2消費率、
(v)増加したATP産生率、または
(vi)それらの任意の組み合わせ
のうちの少なくとも1つを有する、請求項1~5のいずれか一項に記載の医薬組成物。 - 前記ヒトCD34 + 幹細胞が、前記外因性ミトコンドリアで富化される前の前記患者から得られるかまたは由来する、請求項1~6のいずれか一項に記載の医薬組成物。
- 前記ヒトCD34 + 幹細胞が、前記外因性ミトコンドリアで富化される前の前記患者とは異なるドナーから得られるかまたは由来する、請求項1~6のいずれか一項に記載の医薬組成物。
- 前記ドナーが、少なくとも部分的に前記患者とHLA適合するか、または
前記治療が、前記患者と前記ミトコンドリア富化ヒトCD34 + 幹細胞との間の有害な免疫原性反応、例えば移植片対宿主病(GvHD)など、を防止、遅延、最小化、もしくは無効化する薬剤を前記患者に投与することをさらに含む、
請求項8に記載の医薬組成物。 - 前記ヒトCD34 + 幹細胞が、造血幹細胞であるか、または
前記ヒトCD34 + 幹細胞が、間葉系幹細胞であるか、または
前記ヒトCD34 + 幹細胞が、多能性幹細胞(PSC)もしくは人工多能性幹細胞(iPSC)である、
請求項1~9のいずれか一項に記載の医薬組成物。 - 前記ヒトCD34 + 幹細胞が、ヒト外因性ミトコンドリアを前記ヒトCD34 + 幹細胞に導入する前に、少なくとも1回の凍結-解凍サイクルを受けているか、または
前記ヒトCD34 + 幹細胞が、前記ヒト外因性ミトコンドリアでの富化後に、少なくとも1回の凍結-解凍サイクルを受けている、
請求項2~10のいずれか一項に記載の医薬組成物。 - 前記ヒトCD34 + 幹細胞が、骨髄、脂肪組織、口腔粘膜、皮膚線維芽細胞、血液、もしくは臍帯血の細胞から単離されるか、由来するか、もしくは得られる、または
前記ヒト外因性ミトコンドリアが、胎盤、培養で成長させた胎盤細胞、もしくは血液細胞から単離されるかもしくは得られる、
請求項1~11のいずれか一項に記載の医薬組成物。 - 前記ヒト外因性ミトコンドリアが、前記ミトコンドリア富化ヒトCD34 + 幹細胞中の全ミトコンドリアの少なくとも1%を構成するか、または
前記ヒト外因性ミトコンドリアが、前記ミトコンドリア富化ヒトCD34 + 幹細胞中の全ミトコンドリアの少なくとも3%を構成するか、または
前記ヒト外因性ミトコンドリアが、前記ミトコンドリア富化ヒトCD34 + 幹細胞中の全ミトコンドリアの少なくとも10%を構成する、
請求項1~12のいずれか一項に記載の医薬組成物。 - 非富化幹細胞、巨核球、赤血球、肥満細胞、骨髄芽球、好塩基球、好中球、好酸球、単球、マクロファージ、ナチュラルキラー(NK)細胞、小リンパ球、Tリンパ球、Bリンパ球、形質細胞、細網細胞、またはそれらの任意の組み合わせから選択される細胞をさらに含む、請求項1~13のいずれか一項に記載の医薬組成物。
- 前記増加したミトコンドリアDNA含有量が、内因性および/または外因性ミトコンドリアに由来する、請求項6に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862701783P | 2018-07-22 | 2018-07-22 | |
US62/701,783 | 2018-07-22 | ||
US201862753937P | 2018-11-01 | 2018-11-01 | |
US62/753,937 | 2018-11-01 | ||
PCT/IL2019/050826 WO2020021539A1 (en) | 2018-07-22 | 2019-07-22 | Mitochondrial augmentation therapy of muscle diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021532094A JP2021532094A (ja) | 2021-11-25 |
JPWO2020021539A5 JPWO2020021539A5 (ja) | 2022-06-28 |
JP7458368B2 true JP7458368B2 (ja) | 2024-03-29 |
Family
ID=69181527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021502836A Active JP7458368B2 (ja) | 2018-07-22 | 2019-07-22 | 筋疾患のミトコンドリア増強療法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11951135B2 (ja) |
EP (1) | EP3823640A4 (ja) |
JP (1) | JP7458368B2 (ja) |
WO (1) | WO2020021539A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2741757B1 (en) | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
US20210275587A1 (en) * | 2018-07-22 | 2021-09-09 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018507690A (ja) | 2015-02-26 | 2018-03-22 | ミノヴィア セラピューティクス リミテッド | 機能性ミトコンドリアで富化された哺乳動物細胞 |
WO2018101708A1 (ko) | 2016-11-30 | 2018-06-07 | 차의과학대학교 산학협력단 | 미토콘드리아를 포함하는 약학 조성물 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9507241A (pt) | 1994-03-30 | 1997-09-16 | Mitokor | Processos para detectar a presença de doença de alzheimer e de origem mitocondrial em um indivíduo e as mutações genéticas que provocam doença de alzheimer para inibir a transcrição ou tradução de genes e de um ou mais ácidos nucleicos codificando oxidase de citocromo c mutante para introduzir seletivamente uma molécula conjugada em mitocôndrias para construir uma linhagem de células para avaliar um composto para utilidade em potencial no diagnóstico de distúrbios no tratamento de um distúrbio eno diagnóstico ou tratamento de diabetes mellitus para preparar um animal cibrido e para determinar a presença de uma doença humana de origem mitoconddrial sequências de nucleotideos isoladas sonda kit composição terapêutica ribozima linhagem de cêlulas e animal cibrido |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
IL139321A0 (en) | 1999-03-03 | 2001-11-25 | Biogen Inc | Methods and compositions for modulating lipid metabolism |
GB2350565A (en) | 1999-05-28 | 2000-12-06 | Johnson & Johnson Medical Ltd | Biological wound dressings comprising mitochondria |
DE19937348A1 (de) | 1999-08-11 | 2001-02-22 | Aventis Cropscience Gmbh | Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind |
US7238727B2 (en) | 2000-10-13 | 2007-07-03 | Chugai Seiyaku Kabushiki Kaisha | Compositions for improving lipid metabolism |
US20030040475A1 (en) | 2001-01-16 | 2003-02-27 | Yasuhiro Toba | Agents for improving lipid metabolism and reducing high blood pressure |
US7339090B2 (en) | 2001-02-13 | 2008-03-04 | Avigenics, Inc. | Microinjection devices and methods of use |
JP4603192B2 (ja) | 2001-05-10 | 2010-12-22 | 株式会社カネカ | 毛髪頭皮用組成物 |
WO2003012050A2 (en) | 2001-07-31 | 2003-02-13 | Northeastern University | Mitochondrial genome replenishment |
US20050153381A1 (en) | 2002-02-14 | 2005-07-14 | Marusich Michael F. | Immunocapture of mitochondrial protein complexes |
EP1633768A2 (en) | 2003-05-13 | 2006-03-15 | The Regents Of The University Of Colorado | Diagnostic and therapeutic treatments related to mitochondrial disorders |
JP4991297B2 (ja) | 2003-05-22 | 2012-08-01 | キエジ ファルマチェウティチ エッセ・ピ・ア | 細胞死を予防および治療するための手段およびそれらの生物学的適用 |
US7407800B1 (en) | 2003-09-19 | 2008-08-05 | Pierce Biotechnology, Inc. | Method for the isolation of intact mitochondria from cells |
EP1709084A4 (en) | 2003-12-23 | 2008-05-28 | Nono Inc | POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS |
US20060024277A1 (en) | 2004-07-27 | 2006-02-02 | Sivak Hannah N | Method of skin care and/or treatment using extracts enriched in mitochondria |
WO2006132586A1 (en) | 2005-06-10 | 2006-12-14 | Per-Ake Albertsson | Use of plant cell membrane for the for the treatment of obesity |
AU2012201710B2 (en) | 2006-05-11 | 2014-01-16 | Regenics As | Administration of cells and cellular extracts for rejuvenation |
AT502353B1 (de) | 2006-06-29 | 2007-07-15 | Avl List Gmbh | Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases |
US9603872B2 (en) | 2007-05-02 | 2017-03-28 | The McLeon Hospital Corporation | Methods and compositions for mitochondrial replacement therapy |
WO2008152640A2 (en) | 2007-06-13 | 2008-12-18 | Pluristem Ltd. | Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells |
WO2009154770A2 (en) | 2008-06-18 | 2009-12-23 | The Texas A & M University System | Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage |
US20110105359A1 (en) | 2009-10-30 | 2011-05-05 | Xenotech, Llc | Cryopreservation of cells and subcellular fractions |
US8338178B2 (en) | 2010-10-28 | 2012-12-25 | The Invention Science Fund I, Llc | Mitochondrial enhancement of cells |
WO2012075319A2 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
CN105497014B (zh) | 2010-12-23 | 2021-03-30 | 阿马曾提斯公司 | 用于改善线粒体功能的组合物和方法 |
WO2013002880A1 (en) | 2011-06-29 | 2013-01-03 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
US20130022666A1 (en) | 2011-07-20 | 2013-01-24 | Anna Brzezinska | Methods and compositions for transfer of mitochondria into mammalian cells |
EP2741757B1 (en) | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
US8648034B2 (en) | 2011-12-09 | 2014-02-11 | Changhua Christian Hospital | Method and applications of peptide-mediated mitochondrial delivery system |
WO2013149064A1 (en) | 2012-03-30 | 2013-10-03 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells |
WO2013171752A1 (en) | 2012-05-16 | 2013-11-21 | Minovia Therapeutics Ltd. | Compositions and methods for inducing angiogenesis |
EP3459522B1 (en) | 2012-12-10 | 2021-02-17 | Regenics AS | Use of egg cellular extracts for wound treatment |
DE102013225588A1 (de) | 2013-12-11 | 2014-04-17 | Henkel Ag & Co. Kgaa | Verwendung und Mittel zur Verbesserung der Haarstruktur |
KR20160113295A (ko) | 2014-02-04 | 2016-09-28 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
EP2918458B1 (en) | 2014-03-11 | 2016-12-07 | Autoliv Development AB | A vehicle braking arrangement |
MA40253A (fr) | 2014-07-15 | 2017-05-24 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
EP3169338A1 (en) | 2014-07-16 | 2017-05-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for the intercellular transfer of isolated mitochondria in recipient cells |
JP6441472B2 (ja) | 2014-09-30 | 2018-12-19 | 台灣粒線體應用技術股▲扮▼有限公司Taiwan Mitochondrion Applied Technology Co.,Ltd. | 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法 |
GB201500427D0 (en) | 2015-01-12 | 2015-02-25 | Isis Innovation | Method |
US20180007913A1 (en) | 2015-01-14 | 2018-01-11 | Calix Ltd | Improved pathogen inhibitor |
JP2018507865A (ja) | 2015-02-27 | 2018-03-22 | ユニバーシティ オブ コネチカット | 肝細胞へのミトコンドリアの標的化移植 |
EP3383411A4 (en) | 2015-11-30 | 2019-07-03 | Flagship Pioneering Innovations V, Inc. | METHODS AND COMPOSITIONS RELATING TO CHONDRISOMES FROM CULTIVATED CELLS |
EP3402490B1 (en) | 2016-01-15 | 2022-06-01 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
CA3042360A1 (en) | 2016-11-03 | 2018-05-11 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
KR101846460B1 (ko) | 2016-11-14 | 2018-04-09 | 주식회사 파이안바이오테크놀로지 | 외래 미토콘드리아를 세포로 전달하는 방법 |
US20200023005A1 (en) | 2017-03-26 | 2020-01-23 | Minovia Therapeutics Ltd. | Mitochondrial compositions and methods for treatment of skin and hair |
JP2021531288A (ja) | 2018-07-22 | 2021-11-18 | ミノヴィア セラピューティクス リミテッド | 眼疾患のミトコンドリア増強療法 |
EP3823646A4 (en) | 2018-07-22 | 2022-06-08 | Minovia Therapeutics Ltd. | MITOCHONDRIAL AUGMENTATION THERAPY OF BRAIN DISEASES |
MX2021000955A (es) | 2018-07-22 | 2021-05-27 | Minovia Therapeutics Ltd | Terapia de incremento mitocondrial para enfermedades mitocondriales primarias. |
WO2020021537A1 (en) | 2018-07-22 | 2020-01-30 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of liver diseases |
EP3823644A4 (en) | 2018-07-22 | 2022-06-08 | Minovia Therapeutics Ltd. | MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES |
JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
MX2021000954A (es) | 2018-07-22 | 2021-03-31 | Minovia Therapeutics Ltd | Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales. |
WO2020036973A1 (en) | 2018-08-14 | 2020-02-20 | Imel Biotherapeutics, Inc. | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy |
SG11202111824UA (en) | 2019-04-30 | 2021-11-29 | Larimar Therapeutics Inc | Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy |
CA3172402A1 (en) | 2020-03-31 | 2021-10-07 | Minovia Therapeutics Ltd. | Mitochondria-enriched genetically engineered cells and uses thereof |
-
2019
- 2019-07-22 JP JP2021502836A patent/JP7458368B2/ja active Active
- 2019-07-22 EP EP19840137.4A patent/EP3823640A4/en active Pending
- 2019-07-22 US US17/255,396 patent/US11951135B2/en active Active
- 2019-07-22 WO PCT/IL2019/050826 patent/WO2020021539A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018507690A (ja) | 2015-02-26 | 2018-03-22 | ミノヴィア セラピューティクス リミテッド | 機能性ミトコンドリアで富化された哺乳動物細胞 |
WO2018101708A1 (ko) | 2016-11-30 | 2018-06-07 | 차의과학대학교 산학협력단 | 미토콘드리아를 포함하는 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US11951135B2 (en) | 2024-04-09 |
JP2021532094A (ja) | 2021-11-25 |
WO2020021539A9 (en) | 2020-06-18 |
WO2020021539A1 (en) | 2020-01-30 |
EP3823640A4 (en) | 2022-05-18 |
EP3823640A1 (en) | 2021-05-26 |
US20210290691A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7454548B2 (ja) | 膵臓疾患のミトコンドリア増強療法 | |
US20210275597A1 (en) | Mitochondrial augmentation therapy of ocular diseases | |
US20210275599A1 (en) | Mitochondrial augmentation therapy of brain diseases | |
US20210252075A1 (en) | Mitochondrial augmentation therapy of liver diseases | |
JP7458368B2 (ja) | 筋疾患のミトコンドリア増強療法 | |
US20210322485A1 (en) | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria | |
US20210260137A1 (en) | Mitochondrial augmentation therapy for primary mitochondrial diseases | |
US20210275587A1 (en) | Mitochondrial augmentation therapy of renal diseases | |
US20210205368A1 (en) | Mitochondrial augmentation therapy of renal diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220620 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220620 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7458368 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |